				Atto	rney Docket	No.:	
DIVISION - CONTINUATION - CONTINUATION-IN-PART APPLICATION TRANSMITTAL FORM					2836-H		
Cla	•	· · · · · · · · · · · · · · · · · · ·		Prior Applica Examiner	•		Art Unit
	Unknown		Unknown I	Philip Gambe	əl		1644
This is a request for filing a continuation divisional continuation-in-part application, under 37 CFR 1.53(b), of pending prior application Serial No. 10/241,927 filed onSeptember 11, 20_02_, of KENNETH A. BRASEL, STEWART D. LYMAN, EUGENE MARASKOVSKY, HILARY J. MCKENNA AND DAVID H. LYNCH for THE USE OF FLT3-LIGAND IN THE TREATMENT OF INFECTION FOR CONTINUATION or DIVISIONAL APPLNS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 1b, below, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omlitted from the submitted application parts. 1.							
For	Number Filed		Number Extra		Rate		Fee
Total Claims	29	- 20 =	9	X	\$18.00	=	\$ 162.00
Independent Claims	3	- 3 =	0	х	\$84.00	=	0.00
Multiple Dependent Fee	Χ			+	\$280.00	=	280.00
Basic Fee		•			\$750.00	=	750.00
					Total Filing	Fee	\$ 1192.00
 3. Please charge Deposit Account No. 09-0089, in the name of Immunex Corporation, in the amount of \$1192.00. An original and one copy are enclosed. 4. Throughout the prosecution of this application, if any extension of time is necessary, please consider this a request therefor. 5. The Commissioner is hereby authorized to charge any additional filling fees which may be required by the accompanying application, any additional fees which may be required during pendency of this application as required by 37 CFR 1.16 or 1.17, or credit any overpayment to Deposit Account No. 09-0089 throughout the prosecution of this application. 6. Cancel in this application original claims of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.) 							

EXPRESS MAIL CERTIFICATE

"Express Mail" mail labeling number:	El162106242US	Date of Deposit:	August 19, 2003
I hereby certify that this paper or fee is bindicated above and is addressed to Ma	peing deposited with the United States Postal all Stop Patent Application, Commissioner for	f Service "Express Mail Post (r Patents, P.O. Box 1450, Ale:	Office to Addressee" service under 37 CFR 1.10 on the date xandria, VA 22313-1450.
Nanci M	I. Kertson	Same	xandria, VA 22313-1450.
	ed Name		Signature

Docket No.: 2836-H

7. 🛛	The specification has been updated to reflect the following information:					
	This application is a \square continuation \boxtimes division of application Serial No. 10/241,927, filed September 11, 2002, now pending, which is a continuation of application Serial No. 09/444,027, filed November 19, 1999, now abandoned, which is a continuation-in-part of application Serial No. 09/154,903, filed September 17, 1998, now abandoned, which is a continuation-in-part of application Serial No. 08/725,540, filed October 3, 1996; now abandoned, which is a continuation-in-part of application Serial No. 08/539,142, filed October 4, 1995, which are hereby incorporated by reference					
8.	Transfer the drawings from the prior application to this application and abandon said prior application as of the filing date accorded this application. A duplicate copy of this sheet is enclosed for filing in the prior application file. (May only be used if signed by person authorized by § 1.138 and before payment of base issue fee.)					
8a. 🔲	New formal drawings are enclosed.					
9. 🗌	Priority of application Serial No filed on in (country)					
9a. 🔲	The certified copy has been filed in prior application Serial No filed					
10.	The prior application is assigned of record to Immunex Corporation					
11. 🔲	A preliminary amendment is enclosed.					
12. 🛛	Also enclosed Statement Under 37 CFR §1.125; Postcard					
13. 🔲	Other:					
	Address all future communications to					
	James E. Klaniecki					
	at the address below.					
	James E. Klaniecki Attorney/Agent for Applicants Registration No. 38,207					
· 	Phone: (206) 265-4145 Date: August 19, 2003					
	end all future correspondence to:					
Law Dep 51 Unive Seattle, \ (206) 587	rsity Street VA 98101					

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:

Docket No.:

2836-H

Kenneth A. Brasel, Stewart D. Lyman,

Eugene Maraskovsky, Hilary J. McKenna

Group Art Unit: Unknown

Serial No: --to be assigned--

and David H. Lynch

Prior Application:

Divisional of USSN 10/241,927

Examiner: P. Gambel

Filed:

August 19, 2003

For:

THE USE OF FLT3-LIGAND IN THE TREATMENT OF INFECTION

MAIL STOP PATENT APPLICATION Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

STATEMENT UNDER 37 CFR §1.125

Applicants' representative attests that the amendatory material added to the substitute specification for the divisional application of U.S. Patent Application Serial No. 10/241,927 does not constitute new matter. The parent application (i.e., U.S. Patent Application Serial No. 10/241,927) of the presently filed application had incorporated U.S. Patent No. 5,554,512 by reference in its entirety. The amendatory material added to the substitute specification consists of essentially the same material as described in U.S. Patent No. 5,554,512. In addition, a sequence listing has been added to the substitute specification, which had been disclosed in U.S. Patent No. 5,554,512.

James E. Klaniecki

Registration No. 38,207

Immunex Corporation Law Department 51 University Street Seattle, Washington 98101 Ph. (206) 265-4145 Fax (206) 233-0644

eh141004 8/19/03